Madison, WI 的 多發性骨髓瘤 臨床試驗
9 項針對 多發性骨髓瘤 的研究正在 Madison（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
招募中3 期
- Research Site, Madison
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
招募中1/2 期
- University of Wisconsin Carbone Cancer Center, Madison
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中2 期
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
招募中1/2 期
- University of Wisconsin, Madison
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
招募中3 期
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center-University Hospital, Madison
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
招募中3 期
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
招募中2 期
- University of Wisconsin - Carbone Cancer Center, Madison
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
招募中3 期
- University of Wisconsin Hospital and Clinics, Madison
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
招募中2 期
- University of Wisconsin Clinical Science Center, Madison
其他城市的 多發性骨髓瘤 試驗
- New York City, NY60 項研究
- Boston, MA42 項研究
- Atlanta, GA41 項研究
- Houston, TX38 項研究
- Durham, NC37 項研究
- Nashville, TN32 項研究
- Denver, CO27 項研究
- Rochester, MN24 項研究
- St. Louis, MO24 項研究
- Columbus, OH24 項研究
- Baldwin Park, CA23 項研究
- Chicago, IL22 項研究
Madison 的其他研究
- 前列腺癌29 項研究
- 大腸直腸癌22 項研究
- 乳癌22 項研究
- 轉移性癌症21 項研究
- 非小細胞肺癌16 項研究
- 急性髓系白血病16 項研究
- 黑色素瘤15 項研究
- 癌症（所有類型）14 項研究
- 卵巢癌13 項研究
- 胃癌11 項研究
- 肺癌10 項研究
- 胰臟癌10 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。